Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brown University | OTHER |
| Acorda Therapeutics | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.
Subjects will be evaluated before starting medication, throughout a 14week period after starting D-ER as well as at 12 and 18months following the start date of medication regardless of if they stayed on medication or not.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| pwMS prescribed dalfampridine-ER | Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in 25ft walk time | Baseline (pre drug) and followup at 3.5 weeks, 7 weeks, 10.5 weeks and 14weeks | |
| Change in 6 minute walk distance | Measure of endurance | Baseline (pre drug) and followup at 3.5 weeks, 7 weeks, 10.5 weeks and 14weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change of Upper extremity dexterity with 9hole peg test | Baseline (pre drug) and followup at 3.5 weeks, 7 weeks, 10.5 weeks and 14weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Persons with MS who have been prescribed ampyra at the Mandell Center for Multiple Sclerosis.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Albert Lo, M.D, Ph.D. | Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital | Principal Investigator |
| Elizabeth Triche, Ph.D | Brown University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital | Hartford | Connecticut | 06112 | United States |
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
15 mL of blood will be collected into an EDTA tube from participants at assessment appointments. Both serum and cells will be frozen and stored in a -80 degree freezer.
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |